Denali Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Denali Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-68	Closed	-$724	–	506
2023 Q2	$724	Hold	68	–	–	﹤0.01%	454
2023 Q1	$715	Buy	+68	New	+$762	﹤0.01%	411
2022 Q2	–	Sell	-113,600	Closed	-$1.43M	–	400
2022 Q1	$1.43M	Hold	113,600	–	–	0.55%	55
2021 Q4	$1.32M	Buy	+113,600	New	+$1.39M	0.5%	65

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Denali Advisors's IRWD Position: Q3 2023 in Review

Denali Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2023, closing a stake of 68 shares — an estimated $724 sold.

Denali Advisors first reported a position in IRWD in Q4 2021 and held it in 4 quarters. The position peaked at $1.43M in Q1 2022. 248 funds tracked by Wall St. Rank hold IRWD as of Q3 2023.

Denali Advisors reported no remaining Ironwood Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Denali Advisors sold 68 Ironwood Pharmaceuticals shares in Q3 2023, an estimated $724.
Denali Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Denali Advisors's Ironwood Pharmaceuticals position peaked at $1.43M in Q1 2022.
248 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.